You are here
Home > Drugs > XURIDEN ™

Clinical pharmacology

Initial U.S. Approval:  2015
 
Mechanism of Action: Uridine triacetate is an acetylated form of uridine. Following oral administration, uridine triacetate is deacetylated by nonspecific esterases present throughout the body, yielding uridine in the circulation.
XURIDEN provides uridine in the systemic circulation of patients with hereditary orotic aciduria who cannot synthesize adequate quantities of uridine due to a genetic defect in uridine nucleotide synthesis.

Indications and usage 

INDICATIONS AND USAGE:  XURIDEN™ is indicated for the treatment of hereditary orotic aciduria.

Dosage and administration 

Drug UPDATES: XURIDEN ™ - uridine triacetate granule
[Drug information  /  PDF]     Click link for the latest monograph
Dosing:  Click (+) next to Dosage and Administration section (drug info link)

How supplied

HOW SUPPLIED: Oral granules: 2 grams of orange-flavored oral granules (95% w/w) in single-use packets

Reference

[Drug information  /  PDF]     Click link for the latest monograph

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates.  A local search option of this data can be found here.

Disclaimer

The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer